Bluejay Diagnostics (NASDAQ:BJDX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Bluejay Diagnostics (NASDAQ:BJDX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Bluejay Diagnostics Corporate Update: Advancing Clinical Milestones and Strategic Partnerships [Yahoo! Finance]
Bluejay Diagnostics Corporate Update: Advancing Clinical Milestones and Strategic Partnerships
Bluejay Diagnostics (NASDAQ:BJDX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.